Stay updated with breaking news from Multiple Sclerosis Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The investigational evobrutinib, an Bruton's tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.
Data on repair or progression in normal-appearing brain tissue on conventional MRI.
In a randomized trial, depression improved compared to usual neurologist care.
Consumption of a ketogenic diet is safe — and may help reduce disability and improve fatigue and depressive symptoms in patients with relapsing multiple sclerosis (MS), new research suggests.